Immunic Inc (NASDAQ:IMUX) chief scientific officer Dr Hella Kohlhof talked with Proactive's Stephen Gunnion about the significance of Crohn's and Colitis Awareness Week. She outlined the challenges of inflammatory bowel disease (IBD), a chronic and serious condition affecting the digestive tract. "It's not just a regular stomach issue; it's a lifelong disease," she explained, emphasizing the debilitating symptoms such as abdominal pain, fatigue, and weight loss.
Dr Kohlhof discussed Immunic's innovative research projects targeting IBD. The company's IMU-856 aims to restore the gut lining's functionality through epigenetic modulation, while IMU-381 focuses on anti-inflammatory properties, addressing different aspects of gastrointestinal health.
She encouraged viewers to explore resources provided by advocacy groups like the Crohn's and Colitis Foundation and to talk openly about IBD, helping to reduce the stigma and promote awareness. "Please speak about the disease and inform others to see a doctor if they have symptoms," Kohlhof urged.